fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Aflibercept

All injection strengths: Limited Use (codes 729, 730, 731)

Enzeevu · DIN 02562510 · 2 mg/0.05 mL · injection, 0.05 mL pre-filled syringe (preservative-free)

Limited Use, Reason for Use code 729, 730, 731 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 729, 730, 731 required
PolicyOntario biosimilar policy: Eylea available through EAP for approved exceptions; Aflivu, Yesafili available as Limited Use (OHIP bulletin 251105, transition from November 28, 2025). (ontario.ca, Updated November 21, 2025 ↗)
Write on scriptone applicable Reason for Use code, 729 or 730 or 731 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Biosimilar policy source
Biosimilar versions of Eylea® (aflibercept) and Xolair® (omalizumab) were listed on the Formulary as Limited Use Benefits with the August 2025 Formulary update and biosimilar version of Actemra® (tocilizumab) was listed as a Limited Use Benefit with the May 2025 Formulary update. In accordance with this New Start Rule, ODB program recipients who are treatment-naïve will only receive coverage for the biosimilar versions of these biologics, provided that they meet the applicable Limited Use criteria for the products. (ontario.ca, Updated November 21, 2025 ↗) ODB program recipients who are using Eylea®, Actemra®, or Xolair® during the transition period and require continued coverage of their product after the end of the transition period, must have their prescriber apply to the EAP for a medically necessary exemption. Requests for medically necessary exemptions are assessed on a case-by-case basis, and prescribers are encouraged to apply during the transition period to avoid an unintended gap in coverage. Requests for medically necessary exemptions must include documentation that the recipient has tried up to two biosimilar versions (where applicable) and experienced an adverse effect documented on the Health Canada side effect reporting form. A copy of each completed Health Canada reporting form must be included in the EAP request. Medically necessary exemptions will not be considered for ODB recipients subject to the New Start Rule. (ontario.ca, Updated November 21, 2025 ↗)
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 729, 730, 731
Reason for Use code 729 For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye. Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections. Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement. Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 2 months. The interval between two doses should not be shorter than one month. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 730 For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement. Treatment should be initiated with an intravitreal injection once every month. The interval between two doses should not be shorter than one month. The treatment interval may be extended up to 3 months based on visual and anatomic outcomes. Prescribers are advised to periodically assess the need for continued therapy. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year Reason for Use code 731 For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 12 percent. Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement. Treatment should be initiated with a monthly intravitreal injection for the first 5 consecutive doses, followed by one injection every 2 months. The interval between two doses should not be shorter than one month. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy. Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Enzeevu · DIN 02562510 Manufacturer: Sandoz Canada Inc.; listing date 2026-01-30 Health Canada: Marketed since 2026-02-09 · brand ENZEEVU · ATC S01LA05 AFLIBERCEPT · form Solution · route Intravitreal · ingredients AFLIBERCEPT 2 MG/0.05ML · company Sandoz canada incorporated · schedule Prescription, Schedule d
Re-check Health Canada status and shortages (live) · Health Canada product record

Enzeevu: Formulary list price $850.80 per unit (the source does not state the unit; exact figure $850.8000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02562510)

Source record
DIN 02562510: Enzeevu Raw flags: sec12=Y, sec3=Y Item: 520000044; group id 574; item number 1527; lccId 00416; manufacturer id SDZ Source form: Inj Sol-0.05mL Pref Syr (Preservative-Free); strength: 2mg/0.05mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $850.8000; ministry $850.8000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02562510 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106539
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (S01LA): coverage varies; not interchangeable

  • Brolucizumab (Beovu): limited Use 620, 648
  • Faricimab (Vabysmo): limited Use 649, 650, 725
  • Ranibizumab (Byooviz): limited Use 651, 652, 653, 654
Other drugs in the same formulary class (52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS) and how they are covered

Matched class: 52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ATROPINE SULFATE, BETAXOLOL HCL, DEXAMETHASONE, DICLOFENAC SODIUM, FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, FRAMYCETIN SULFATE, FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE, GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, KETOROLAC TROMETHAMINE, LEVOBUNOLOL HCL, LODOXAMIDE TROMETHAMINE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN, TOBRAMYCIN, TOBRAMYCIN & DEXAMETHASONE Some products covered without a code (check the product listing): ACETAZOLAMIDE, BECLOMETHASONE DIPROPIONATE, BUDESONIDE, METHAZOLAMIDE, PILOCARPINE HCL, PREDNISOLONE ACETATE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:04:04 Antibiotics

FRAMYCETIN SULFATE

· 2 products · General benefit · strengths: 0.5% · Oph Oint-5g Pk, Oph Sol

FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE

· 1 products · General benefit · strengths: 5mg & 50mcg & 0.5mg/mL · Oph/Ot Sol

GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE

· 1 products · General benefit · strengths: 3mg & 1mg/mL · Oph/Ot Drops

GENTAMICIN SULFATE

· 1 products · General benefit · strengths: 0.3% · Oph Oint-3.5g Pk

POLYMYXIN B SULFATE & BACITRACIN (ZINC)

· 1 products · General benefit · strengths: 10000U & 500U/g · Oph Oint 3.5g Pk

POLYMYXIN B SULFATE & GRAMICIDIN

· 1 products · General benefit · strengths: 10000U & 0.025mg/mL · Oph/Ot Sol

TOBRAMYCIN

· 3 products · General benefit · strengths: 0.3% · Oph Oint, Oph Sol

TOBRAMYCIN & DEXAMETHASONE

· 2 products · General benefit · strengths: 0.3% & 0.1% · Oph Oint, Oph Susp

CIPROFLOXACIN AND DEXAMETHASONE

· 3 products · Limited Use, codes 509 · strengths: 0.3% w/v & 0.1% w/v · Otic Susp-7.5mL Pk (With Preservative)

GATIFLOXACIN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% w/v · Oph Sol

MOXIFLOXACIN HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5% · Oph Sol-3mL Pk (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:04:04 52:04:12 Other Anti-Infectives

OFLOXACIN

· 1 products · Limited Use, codes 170 · strengths: 0.3% · Oph Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:04:12 and 53 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: diabetic macular edema, neovascular, visual impairment
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BROLUCIZUMAB · Limited Use, codes 620, 648 1 INDICATIONS BEOVU® (brolucizumab injection) is indicated for: • The treatment of neovascular (wet) age-related macular degeneration (AMD). PM: https://pdf.hres.ca/dpd_pm/00077080.PDF; date Mar 12, 2020; DIN 02496976; fetched 2026-09-10 Product monograph • The treatment of diabetic macular edema (DME). PM: https://pdf.hres.ca/dpd_pm/00077080.PDF; date Mar 12, 2020; DIN 02496976; fetched 2026-09-10 Product monograph RANIBIZUMAB · Limited Use, codes 651, 652, 653, 654 1 Indications MELVIZO (ranibizumab injection) is indicated for: • the treatment of neovascular (wet) age-related macular degeneration (AMD). PM: https://pdf.hres.ca/dpd_pm/00082902.PDF; date November 7, 2025; DIN 02525852; fetched 2026-09-10 Product monograph • the treatment of visual impairment due to diabetic macular edema (DME). PM: https://pdf.hres.ca/dpd_pm/00082902.PDF; date November 7, 2025; DIN 02525852; fetched 2026-09-10 Product monograph • the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO). PM: https://pdf.hres.ca/dpd_pm/00082902.PDF; date November 7, 2025; DIN 02525852; fetched 2026-09-10 Product monograph • the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM). PM: https://pdf.hres.ca/dpd_pm/00082902.PDF; date November 7, 2025; DIN 02525852; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS Indications have been granted on the basis of similarity between YESAFILI and the reference biologic drug EYLEA®. YESAFILI (aflibercept, solution for intravitreal injection) is indicated for: • the treatment of neovascular (wet) age-related macular degeneration (AMD) • the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) • the treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) • the treatment of diabetic macular edema (DME) • the treatment of myopic choroidal neovascularization (myopic CNV) 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and effectiveness of YESAFILI in pediatric patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Clinical studies of YESAFILI include participants 65 years of age and older. No clinically significant differences in efficacy or safety were seen with increasing age in these studies. https://pdf.hres.ca/dpd_pm/00084821.PDF PM date: 2026-05-22 Source product: YESAFILI; DIN 02535858; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18